Please ensure Javascript is enabled for purposes of website accessibility

Why Pacific Biosciences of California Stock Is Skyrocketing Today

By Keith Speights – Nov 2, 2018 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.

What happened

Shares of Pacific Biosciences of California (PACB -2.59%) skyrocketed on Friday, up 66.9% as of 10:48 a.m. EDT. There's nothing like a big buyout to excite investors -- and that's exactly what happened for PacBio. Gene-sequencing giant Illumina (ILMN -1.61%) announced on Thursday evening that it plans to acquire PacBio for $1.2 billion. The news came at the same time PacBio reported dismal third-quarter results

So what

It's important to understand just how great the Illumina acquisition is for PacBio shareholders. Illumina's offer of $8 per share represented a 71% premium over PacBio's 30-trading-day volume-weighted average share price as of the market close on Oct. 31, 2018. The $1.2 billion total price tag of the deal is well above PacBio's highest market cap ever.

Palm extended with image of DNA double helix hovering above it

Image source: Getty Images.

But aside from the fantastic financial gains associated with the acquisition, joining Illumina could open up new opportunities for PacBio's technology. PacBio made its mark by developing long-read sequencing systems, while Illumina focused on short-read sequencing. Long-read sequencing is a lot more expensive than short-read sequencing, but it's better suited for certain applications.

With PacBio becoming part of Illumina, customers will be able to go to one vendor to meet all their sequencing needs. Illumina also brings the capital needed to fund further development of PacBio's single molecule real time (SMRT) sequencing technology. Over the years, Illumina has driven the cost of short-read sequencing down tremendously. It just might be able to accomplish a similar feat in long-read sequencing.

PacBio was doing pretty well on its own this year. Its share price was up more than 60% even before the Illumina buyout news. However, the company fell victim to its own success in a way in the third quarter. Customers appeared to hold off on placing orders while they waited on new products that PacBio was introducing to the market.

Now what

Illumina stated that it expects the acquisition of PacBio to close in the middle of 2019. While investors wait for the transaction to finalize, they could see more good news for PacBio.

CEO Mike Hunkapillar said that the company has been "very pleased with the enthusiastic response from our customers on the launch of our new 3.0 chemistry and 6.0 software in October." In addition, PacBio plans to launch its new 8M SMRT Cell and platform in the first quarter of 2019.

Keith Speights owns shares of Illumina. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Pacific Biosciences of California. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
$5.27 (-2.59%) $0.14
Illumina, Inc. Stock Quote
Illumina, Inc.
$190.38 (-1.61%) $-3.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.